Literature DB >> 16973749

A rationally designed agonist antibody fragment that functionally mimics thrombopoietin.

Shana Frederickson1, Mark W Renshaw, Bing Lin, Lynette M Smith, Peter Calveley, Jeremy P Springhorn, Krista Johnson, Yi Wang, Xiao Su, Yamin Shen, Katherine S Bowdish.   

Abstract

By using rational design, antibody fragments (Fabs) that mimic thrombopoietin (TPO) were created. A peptide with cMpl receptor-binding capability was grafted into different complementarity-determining regions of a fully human Fab scaffold. Functional presentation of the peptide was optimized by using phage display and cell-based panning. Select antibodies and fragments containing two grafted peptides were assayed for their ability to stimulate the cMpl receptor in vitro. Several candidates demonstrated agonist activity in an in vitro cMpl receptor signaling reporter assay, including Fab59, which was estimated to be equipotent to TPO. Fab59 additionally was able to effectively stimulate platelet production in normal mice. These rationally designed mimetic Fabs may provide a therapeutic intervention for thrombocytopenia while avoiding the potential generation of neutralizing antibodies to endogenous TPO. Furthermore, this study demonstrates a method by which short-lived linear peptides with binding activity may be converted to more stable and potent agonists capable of activating cell surface receptors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16973749      PMCID: PMC1599960          DOI: 10.1073/pnas.0602658103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer.

Authors:  S Vadhan-Raj; L J Murray; C Bueso-Ramos; S Patel; S P Reddy; W K Hoots; T Johnston; N E Papadopolous; W N Hittelman; D A Johnston; T A Yang; V E Paton; R L Cohen; S D Hellmann; R S Benjamin; H E Broxmeyer
Journal:  Ann Intern Med       Date:  1997-05-01       Impact factor: 25.391

2.  High-affinity self-reactive human antibodies by design and selection: targeting the integrin ligand binding site.

Authors:  C F Barbas; L R Languino; J W Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

3.  Discovery of a novel thrombopoietin mimic agonist peptide.

Authors:  T Kimura; H Kaburaki; S Miyamoto; J Katayama; Y Watanabe
Journal:  J Biochem       Date:  1997-11       Impact factor: 3.387

4.  Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine.

Authors:  S E Cwirla; P Balasubramanian; D J Duffin; C R Wagstrom; C M Gates; S C Singer; A M Davis; R L Tansik; L C Mattheakis; C M Boytos; P J Schatz; D P Baccanari; N C Wrighton; R W Barrett; W J Dower
Journal:  Science       Date:  1997-06-13       Impact factor: 47.728

5.  Human fos gene.

Authors:  I M Verma; J Deschamps; C Van Beveren; P Sassone-Corsi
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1986

6.  Direct selection of antibodies that coordinate metals from semisynthetic combinatorial libraries.

Authors:  C F Barbas; J S Rosenblum; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

7.  The structure of an antigenic determinant in a protein.

Authors:  I A Wilson; H L Niman; R A Houghten; A R Cherenson; M L Connolly; R A Lerner
Journal:  Cell       Date:  1984-07       Impact factor: 41.582

8.  Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man.

Authors:  M de Serres; B Ellis; J E Dillberger; S K Rudolph; J T Hutchins; C M Boytos; D L Weigl; R B DePrince
Journal:  Stem Cells       Date:  1999       Impact factor: 6.277

9.  Small peptides as potent mimetics of the protein hormone erythropoietin.

Authors:  N C Wrighton; F X Farrell; R Chang; A K Kashyap; F P Barbone; L S Mulcahy; D L Johnson; R W Barrett; L K Jolliffe; W J Dower
Journal:  Science       Date:  1996-07-26       Impact factor: 47.728

10.  The thrombopoietin receptor can mediate proliferation without activation of the Jak-STAT pathway.

Authors:  M Dorsch; P D Fan; N N Danial; P B Rothman; S P Goff
Journal:  J Exp Med       Date:  1997-12-15       Impact factor: 14.307

View more
  12 in total

1.  High affinity anti-inorganic material antibody generation by integrating graft and evolution technologies: potential of antibodies as biointerface molecules.

Authors:  Takamitsu Hattori; Mitsuo Umetsu; Takeshi Nakanishi; Takanari Togashi; Nozomi Yokoo; Hiroya Abe; Satoshi Ohara; Tadafumi Adschiri; Izumi Kumagai
Journal:  J Biol Chem       Date:  2009-12-31       Impact factor: 5.157

2.  Generation of inhibitory monoclonal antibodies targeting matrix metalloproteinase-14 by motif grafting and CDR optimization.

Authors:  Dong Hyun Nam; Kuili Fang; Carlos Rodriguez; Tyler Lopez; Xin Ge
Journal:  Protein Eng Des Sel       Date:  2016-12-15       Impact factor: 1.650

Review 3.  The pharmacology and clinical application of thrombopoietin receptor agonists.

Authors:  Caizheng Li; Li Zheng
Journal:  Int J Hematol       Date:  2014-09-18       Impact factor: 2.490

Review 4.  New thrombopoietic growth factors.

Authors:  David J Kuter
Journal:  Blood       Date:  2007-02-08       Impact factor: 22.113

5.  Engineering a single-chain Fv antibody to alpha v beta 6 integrin using the specificity-determining loop of a foot-and-mouth disease virus.

Authors:  Heide Kogelberg; Berend Tolner; Gareth J Thomas; Danielle Di Cara; Shane Minogue; Bala Ramesh; Serena Sodha; Dan Marsh; Mark W Lowdell; Tim Meyer; Richard H J Begent; Ian Hart; John F Marshall; Kerry Chester
Journal:  J Mol Biol       Date:  2008-07-16       Impact factor: 5.469

6.  Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C.

Authors:  Hans L Tillmann; Keyur Patel; John G McHutchison
Journal:  Curr Gastroenterol Rep       Date:  2009-02

7.  Directed evolution of a three-finger neurotoxin by using cDNA display yields antagonists as well as agonists of interleukin-6 receptor signaling.

Authors:  Mohammed Naimuddin; Suzuko Kobayashi; Chihiro Tsutsui; Masayuki Machida; Naoto Nemoto; Takafumi Sakai; Tai Kubo
Journal:  Mol Brain       Date:  2011-01-07       Impact factor: 4.041

8.  A Novel Peptide Thrombopoietin Mimetic Designing and Optimization Using Computational Approach.

Authors:  Vimal Kishor Singh; Neeraj Kumar; Manisha Kalsan; Abhishek Saini; Ramesh Chandra
Journal:  Front Bioeng Biotechnol       Date:  2016-08-31

9.  New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents.

Authors:  Ara Metjian; Charles S Abrams
Journal:  Biologics       Date:  2009-12-29

10.  Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim.

Authors:  Barbara Kohn; Gürkan Bal; Aleksandra Chirek; Sina Rehbein; Abdulgabar Salama
Journal:  BMC Vet Res       Date:  2016-06-10       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.